mdt revenu growth fiscal came better expect solid growth
across everi divis controversi quarter diabet
lower full year guidanc low singl digit growth previou guidanc
growth equat roughli reduct chang total
compani guidanc despit lower diabet guid
better expect inde continu expect acceler next
two quarter overal invest thesi remain much
intact updat estim reflect quarter reiter buy rate
regard diabet timelin remain unchang result littl better
model due strength outsid us guidanc reduct
full year back half driven mdt assumpt patient take
advantag upgrad offer caus defer revenu recognit
avail model diabet revenu growth
diabet revenu growth look forward hear new
diabet divis head outlook divis strateg decis may
make stand today may truli competit platform sever year
even assum progress monitor accuraci area
struggl year diabet potenti swing growth
meaning enough warrant signific attent insid detail
mdt ischem stroke growth high rang growth outsid
us mid-teen growth us clearli lose share stroke gain
peripher state tavr growth acceler last week
quarter launch evolut pro think much posit comment
market comment market share also comment
improv trial trend spinal cord stimul posit market
anoth small posit insid detail
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
medic devic compani
oper four busi segment cardiac
diabet group minim invas therapi
buy rate continu believ
cov deal lower risk profil
better posit win new healthcar
environ longer term exposur
major med-tech growth market see
enough pipelin deliv
revenu growth ep growth go
detail back half growth dynam
one area debat quarter growth rate impli approxim
growth guidanc year impli back half growth deceler year stack
basi despit much easier comp first two quarter fiscal
look growth rate experienc howev note
look growth put actual growth rate dictat larg
part happen first half sap outag hurrican puerto rico
creat realli easi comp first half fy look growth
second quarter growth acceler comp-adjust basi almost
point growth remain fairli stabl look growth
comp-adjust basi look growth year comp-adjust appear
deceler point term driver back
half recal first quarter issu impact lvad anniversari
help growth cvg linq launch also
benefit interstim micro interstim ii next gen micraav back half
med-tech tabl quarter
tabl med-tech organ growth trend compani
averag excl ew
average excl ew
tabl diabet set dispos revenu
price object base trade ep
slight discount peer approx think small discount group
warrant given recent execut misstep sever revenu headwind
upsid risk price object greater-than-expect revenu growth new
product robot develop market share gain competit product delay
acceler end-market growth downsid risk price object
competit share loss and/or price pressur
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
